Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of danegaptide in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Trial Profile

A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of danegaptide in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danegaptide (Primary)
  • Indications Myocardial infarction; Myocardial reperfusion injury
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 02 Mar 2016 According to a Zealand Pharma media release, the company announced top line results from this phase II Proof-of-Concept trial of danegaptide for the protection against cardiac reperfusion injuries in patients with an acute myocardial infarction.
    • 02 Mar 2016 Primary endpoint [Myocardial Salvage Index [ Time Frame: 3 months ] [ Designated as safety issue: No ] Myocardial Salvage Index as assessed by MRI and calculated as the difference between myocardial volume at risk and final infarct size in relation to myocardial volume at riskhas not been met. (Myocardial Salvage Index)] has not been met.
    • 14 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top